ADI Announces U.S. FDA 510(k) Clearance and the Commercial Launch of Sensinel by Analog Devices™ Cardiopulmonary Management (CPM) System
WILMINGTON, Mass., March 5, 2024 /PRNewswire/ -- Analog Devices, Inc. (Nasdaq: ADI) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the commercial launch of the Sensinel™ Cardiopulmonary Management (CPM) System. The compact wearable device is a non-invasive, remote management system that captures cardiopulmonary measurements for chronic disease management such as heart failure. It is the first FDA clearance the company has received in its 59-year history.
- WILMINGTON, Mass., March 5, 2024 /PRNewswire/ -- Analog Devices, Inc. (Nasdaq: ADI ) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the commercial launch of the Sensinel™ Cardiopulmonary Management (CPM) System.
- The compact wearable device is a non-invasive, remote management system that captures cardiopulmonary measurements for chronic disease management such as heart failure.
- "Since our founding, ADI has focused on accelerating breakthroughs that enrich lives through innovative products," said Patrick O'Doherty, Senior Vice President of Digital Healthcare at ADI.
- The Sensinel CPM System is the next-generation solution for management of cardiopulmonary diseases like heart failure.